Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2019

View Archived Issues

Ebola antibody cocktail is drug development model

In immunotherapy, translation's translational potential

Anxiety affects weight via BDNF, inhibitory neurons

Enrollment ongoing in phase I study of MRX-0518 plus pembrolizumab in patients with solid tumors

FDA accepts IND application for phase I/II study of AVR-RD-04 gene therapy for cystinosis

Fat and happy: combination treatment subverts tumor cell plasticity

OliX nominates OLX-10020 as a clinical candidate for geographic atrophy

Celgene enters two cancer immunotherapy collaborations

Xiamen University divulges RET inhibitors

Selvita presents adenosine A2A receptor antagonists

Aradigm releases third-party evaluation results of Apulmiq phase III trials

Preliminary phase Ib data presented for GLS-010 in patients with advanced gastrointestinal tumors

Phase I results reported for galunisertib plus SBRT in advanced hepatocellular carcinoma

Canerpaturev plus standard chemotherapy shows encouraging antitumor activity in pancreatic cancer

Phase III ANNOUNCE study of Lartruvo in soft tissue sarcoma does not meet primary endpoints

Phase III RESOLVE trial of ibrutinib in metastatic pancreatic cancer misses primary endpoint

Gilead presents phase III data for andecaliximab combined with chemotherapy

FDA approves trastuzumab biosimilar Ontruzant

Redx receives MHRA clearance to resume RXC-004 clinical trial program

First-in-human study evaluates EMB-01 in advanced/metastatic solid tumors

Syntrix opens enrollment for phase I study of SX-682 in metastatic melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...